Continuous activation of FOXO3 led to drug resistance in CML cells after tyrosine kinase inhibitor or imatinib therapy (Hui et al., 2008a; Hui et al., 2008b; Naka et al., 2010). The gene discussed is FOXO3; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.